List view / Grid view
17 January 2025 | By Drug Target Review
Join this webinar to learn how organoids are reshaping drug discovery by providing more accurate models for disease research and drug testing, offering new solutions to long-standing challenges in the industry.
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
Anirban Datta, Head of Discovery Biology at Verseon International Corporation, details how recent breakthroughs are bringing once-distant possibilities, such as testing drugs more efficiently and restoring lost organ function through implantation, closer to reality.
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
Understanding the signalling pathway controlling neural stem cell reactivation could offer a strategy for using existing drugs to treat neurodevelopmental disorders.
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
